Ahmed Ali1,2, Samar Farid3, Mona Amin4, Mohamed Kassem5, Nouman Al-Garem4, Medhat Al-Ghobashy6,7. 1. Department of Pharmaceutics, Egyptian Russian University, Badr City, Egypt. ahmedclinicalbcps@yahoo.com. 2. , Qualiobia, Shebeen-Elquanater, Kafr Taha, Egypt. ahmedclinicalbcps@yahoo.com. 3. Department of Clinical Pharmacy, Cairo University, Cairo, Egypt. 4. Department of Internal Medicine, Cairo University, Cairo, Egypt. 5. Department of Pharmaceutics, Cairo University, Cairo, Egypt. 6. Analytical Chemistry Department, Faculty of Pharmacy, Cairo University, Cairo, Egypt. 7. Bioanalysis Research Group, Faculty of Pharmacy, Cairo University, Cairo, Egypt.
Abstract
OBJECTIVE: Midodrine is an α-agonist prodrug of desglymidodrine used for the management of hypotension, and can also be used for hepatorenal syndrome and cirrhotic patients with tense ascites. The objective of the present work was to study the clinical pharmacokinetic parameters of midodrine and its active metabolite desglymidodrine in cirrhotic patients with tense ascites, which may help in dose selection and improve treatment outcome. METHOD: This was a prospective, open-label, single-dose, parallel-group study. At first, a pilot study was performed on one healthy volunteer by taking serial blood samples at scheduled time intervals to validate the method of analysis and sampling times. The full study was then conducted by selecting 12 cirrhotic patients with tense ascites in one group and taking nine blood samples. We also selected five healthy volunteers as the control group and took 11 blood samples. RESULTS: Statistically significant differences were observed between the healthy volunteer group and the patients group in the area under the concentration versus time curve (AUC0-t) and maximum plasma concentration (Cmax) values of midodrine and desglymidodrine. Based on the results of the pharmacokinetic analysis, the patient group was further subdivided into those receiving the interacting drug ranitidine (five patients) and those not receiving the interacting drug (seven patients). CONCLUSIONS: Pharmacokinetic parameters of midodrine can differ significantly in cirrhotic patients with tense ascites from those in healthy individuals. Drug monitoring, dose adjustments, and drug-drug interactions should all be considered during therapy in this vulnerable patient group.
OBJECTIVE:Midodrine is an α-agonist prodrug of desglymidodrine used for the management of hypotension, and can also be used for hepatorenal syndrome and cirrhoticpatients with tense ascites. The objective of the present work was to study the clinical pharmacokinetic parameters of midodrine and its active metabolite desglymidodrine in cirrhoticpatients with tense ascites, which may help in dose selection and improve treatment outcome. METHOD: This was a prospective, open-label, single-dose, parallel-group study. At first, a pilot study was performed on one healthy volunteer by taking serial blood samples at scheduled time intervals to validate the method of analysis and sampling times. The full study was then conducted by selecting 12 cirrhoticpatients with tense ascites in one group and taking nine blood samples. We also selected five healthy volunteers as the control group and took 11 blood samples. RESULTS: Statistically significant differences were observed between the healthy volunteer group and the patients group in the area under the concentration versus time curve (AUC0-t) and maximum plasma concentration (Cmax) values of midodrine and desglymidodrine. Based on the results of the pharmacokinetic analysis, the patient group was further subdivided into those receiving the interacting drug ranitidine (five patients) and those not receiving the interacting drug (seven patients). CONCLUSIONS: Pharmacokinetic parameters of midodrine can differ significantly in cirrhoticpatients with tense ascites from those in healthy individuals. Drug monitoring, dose adjustments, and drug-drug interactions should all be considered during therapy in this vulnerable patient group.
Authors: Thorir D Bjornsson; John T Callaghan; Heidi J Einolf; Volker Fischer; Lawrence Gan; Scott Grimm; John Kao; S Peter King; Gerald Miwa; Lan Ni; Gondi Kumar; James McLeod; R Scott Obach; Stanley Roberts; Amy Roe; Anita Shah; Fred Snikeris; John T Sullivan; Donald Tweedie; Jose M Vega; John Walsh; Steven A Wrighton Journal: Drug Metab Dispos Date: 2003-07 Impact factor: 3.922
Authors: David Paling; Arturo Vilches-Moraga; Qasim Akram; Oliver Atkinson; John R Staniland; E Paredes-Galán Journal: J Am Geriatr Soc Date: 2010-10 Impact factor: 5.562
Authors: Jill M Wecht; Dwindally Rosado-Rivera; John P Handrakis; Miroslav Radulovic; William A Bauman Journal: Arch Phys Med Rehabil Date: 2010-09 Impact factor: 3.966
Authors: Ahmed A Ali; Medhat A Al-Ghobashy; Samar F Farid; Mohamed A Kassem Journal: J Chromatogr B Analyt Technol Biomed Life Sci Date: 2015-04-07 Impact factor: 3.205